PMID: 6238116Nov 1, 1984Paper

Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex)

The Journal of Endocrinology
K WalkerK Griffiths


Twenty two patients with advanced carcinoma of the prostate have been treated for up to 3 months with the slow-release (depot) formulation of the luteinizing hormone-releasing hormone (LHRH) agonist ICI 118630. Patients were randomized to receive one of three different doses of ICI 118630 of 0.9, 1.8 or 3.6 mg. The depot preparation was injected subcutaneously every 4 weeks. At the highest dose, the concentration of testosterone in serum was significantly reduced to castrate values after 2-3 weeks of therapy. The smaller doses of ICI 118630 (1.8 or 0.9 mg every 4 weeks) similarly reduced serum testosterone concentrations although, at the lowest dose, testosterone values were not suppressed in all patients during the first month. Hormonal changes were accompanied by subjective clinical improvement in symptomatic patients and there were no significant side effects. The data clearly demonstrate the considerable therapeutic potential of ICI 118630 in the depot formulation for the treatment of advanced carcinoma of the prostate.


Jan 1, 1990·International Urology and Nephrology·P KlarskovS E Petersen
Aug 30, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·H B RavivarapuP P DeLuca
Mar 1, 1990·Baillière's Clinical Endocrinology and Metabolism·C L Eaton, K Griffiths
Nov 1, 1985·Journal of Steroid Biochemistry·R I NicholsonR W Blamey
Mar 1, 1987·Clinical Endocrinology·R N Clayton
Jan 1, 1988·Critical Reviews in Oncology/hematology·L J SwansonM B Garnick
Feb 1, 1987·Baillière's Clinical Endocrinology and Metabolism·H M Fraser, D T Baird
Aug 30, 2013·Expert Opinion on Pharmacotherapy·Ferenc G RickAndrew V Schally
Feb 1, 1991·Neuropathology and Applied Neurobiology·H RadnerH Höfler
Dec 15, 1993·Cancer·P FerrariA Dotti
Dec 15, 1993·Cancer·C Mahler
Dec 15, 1993·Cancer·K Griffiths
May 1, 1986·British Journal of Obstetrics and Gynaecology·R I McLachlanH G Burger
Nov 28, 2002·Clinical Pharmacokinetics·Yie W Chien, Senshang Lin
May 28, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Pravien RajaramQiao-Hong Chen
Mar 21, 2007·Molecular and Cellular Endocrinology·Jason P MansellSarah J Yarram

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.